EVerMed is pleased to announce that our lead pipeline candidate, EM-001, has been selected by the Japan Agency for Medical Research and Development (AMED) for its “Support Program for Practical Application of Orphan Drugs Before Designation,” a part of the “Drug Discovery Support Promotion Project.”

Project Title: Clinical Development of Extracellular Vesicle Therapeutic Formulation (EM-001) for Idiopathic Pulmonary Fibrosis

Backed by this prestigious grant and support, EVerMed is fully committed to advancing the clinical development of EM-001, striving to address the unmet medical needs of patients suffering from idiopathic pulmonary fibrosis.